'ESG is regarded as the cornerstone of our sustainable corporate development - aligning directly with our vision and mission – and we take great pride in being responsible stewards of the global environment, while working with global partners to promote sustainable development worldwide. We are committed to delivering a stronger ESG performance for all stakeholders and for the greater good of society.' About WuXi Biologics WuXi Biologics (stock code: 2269.HK) is a global leading Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics from concept to commercialization for the benefit of patients worldwide. With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.